455 Mission Bay Blvd South, Suite 145
San Francisco, CA 94158
ProLynx is a privately held technology platform company. We have developed a technology for the predictable and tunable release of drugs from macromolecular conjugates. Our technology platform uses sets of novel linkers that undergo ? elimination reactions at different, pre-programmed rates to release native drugs ? proteins, peptides and small molecules ? from macromolecular conjugates. Our emphasis is on developing circulating drug conjugates for i.v. or s.c. administration having weekly dosing, and fixed drug conjugates for s.c. implantation having once monthly dosing. We have two existing corporate collaborations. One formed in late 2011 with JNJ and one formed in the fall of 2012 with Bayer HealthCare.
Drug Delivery Technologies
Clinical Development Stage